The Janus Henderson Alternatives grouping includes teams with different areas of focus and approach. The Diversified Alternatives Team brings together a cross-asset class combination of alpha generation, risk management, and efficient beta replication strategies. These include multi-strategy, liquid alternatives, agriculture, and global commodities/managed futures.


Diversified Alternatives

The Janus Henderson Diversified Alternatives Team believes the purpose of Alternative investing is to improve a clients’ risk-return trade-off by providing diversification relative to traditional asset class investments. The team offer solutions aimed at improving clients’ efficient frontiers through global, multi-asset Alternative Risk Premia, Hedge Fund Risk Premia, Enhanced Equity and Commodity Index solutions.


Selling volatility – is the juice still worth the squeeze?

August 30, 2019

Are investors being sufficiently compensated for taking asymmetric risk? In this article, portfolio manager Aneet Chachra and David Elms, Head of Diversified Alternatives, evaluate changing market conditions for equity volatility in the US and UK.

Read More

How much gold?

September 6, 2017

Gold and sovereign bonds are typically the only assets that rise in value during periods of chaos, but at what point does holding gold become detrimental to the performance of a well-diversified portfolio? In this article, fund managers Aneet Chachra and Steve Cain from the Diversified Alternatives team at Janus Henderson explore the value of gold as a hedge against stock drawdowns, particularly for non-US investors, and discuss different ways for investors to start thinking about their own exposure.​

Read More
Factor timing – You’re doing it wrong! | Janus Henderson Investors

Factor timing – You’re doing it wrong!

June 1, 2017

The quantitative finance world has recently been transfixed by its version of the East Coast/West Coast feud. But instead of Brooklyn versus Compton rappers, it’s their suburban cousins Greenwich versus Newport Beach arguing over factor timing.

Read More

In-depth feature

Test tubes | Navigating the drug pricing debate | Janus henderson Investors

Navigating the drug pricing debate

August 3, 2018 | Comments Off on Navigating the drug pricing debate

When the Trump administration introduced a ‘blueprint’ to lower drug prices in May, the pharmaceutical industry breathed a sigh of relief. Andy Acker and Ethan Lovell, Portfolio Managers of the Global Life Sciences strategy, discuss.

Read More